TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
USA - NASDAQ:TMDX - US89377M1099 - Common Stock
134.13 USD
+0.66 (+0.49%)
Taking everything into account, TMDX scores 6 out of 10 in our fundamental rating. TMDX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here. TMDX is growing strongly while it is still valued neutral. This is a good combination! These ratings could make TMDX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in 4 of the past 5 years.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
TMDX's Return On Assets of 9.71% is amongst the best of the industry. TMDX outperforms 92.55% of its industry peers.
TMDX's Return On Equity of 25.88% is amongst the best of the industry. TMDX outperforms 95.74% of its industry peers.
TMDX has a better Return On Invested Capital (8.72%) than 87.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROIC | 8.72% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a Profit Margin of 16.22%. This is amongst the best in the industry. TMDX outperforms 92.55% of its industry peers.
TMDX has a Operating Margin of 16.89%. This is amongst the best in the industry. TMDX outperforms 86.70% of its industry peers.
TMDX's Gross Margin of 60.28% is fine compared to the rest of the industry. TMDX outperforms 60.64% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TMDX is still creating some value.
TMDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
Compared to 1 year ago, TMDX has an improved debt to assets ratio.
2.2 Solvency
TMDX has an Altman-Z score of 5.66. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
TMDX's Altman-Z score of 5.66 is fine compared to the rest of the industry. TMDX outperforms 79.79% of its industry peers.
The Debt to FCF ratio of TMDX is 4.27, which is a neutral value as it means it would take TMDX, 4.27 years of fcf income to pay off all of its debts.
TMDX has a better Debt to FCF ratio (4.27) than 79.79% of its industry peers.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
TMDX has a worse Debt to Equity ratio (1.43) than 80.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Altman-Z | 5.66 |
ROIC/WACC1.08
WACC8.05%
2.3 Liquidity
A Current Ratio of 7.66 indicates that TMDX has no problem at all paying its short term obligations.
TMDX's Current ratio of 7.66 is amongst the best of the industry. TMDX outperforms 89.36% of its industry peers.
A Quick Ratio of 7.10 indicates that TMDX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.10, TMDX belongs to the top of the industry, outperforming 90.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
The Revenue is expected to grow by 21.23% on average over the next years. This is a very strong growth
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 54.30, which means the current valuation is very expensive for TMDX.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than the industry average as 68.62% of the companies are valued more expensively.
TMDX is valuated expensively when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 45.97.
70.21% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
TMDX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 35.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.3 | ||
| Fwd PE | 45.97 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than the industry average as 69.15% of the companies are valued more expensively.
TMDX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.1 | ||
| EV/EBITDA | 37.78 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.74% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:TMDX (11/20/2025, 10:23:39 AM)
134.13
+0.66 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change1.44%
Ins Owners2.96%
Ins Owner Change2.28%
Market Cap4.57B
Revenue(TTM)566.35M
Net Income(TTM)91.86M
Analysts83.16
Price Target149.33 (11.33%)
Short Float %22.8%
Short Ratio7.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-0.07%
PT rev (3m)-3.05%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-4.51%
EPS NY rev (1m)9.57%
EPS NY rev (3m)43.63%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)3.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.3 | ||
| Fwd PE | 45.97 | ||
| P/S | 8.07 | ||
| P/FCF | 38.1 | ||
| P/OCF | 25.69 | ||
| P/B | 12.88 | ||
| P/tB | 13.41 | ||
| EV/EBITDA | 37.78 |
EPS(TTM)2.47
EY1.84%
EPS(NY)2.92
Fwd EY2.18%
FCF(TTM)3.52
FCFY2.62%
OCF(TTM)5.22
OCFY3.89%
SpS16.61
BVpS10.41
TBVpS10
PEG (NY)0.34
PEG (5Y)N/A
Graham Number24.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROCE | 11.04% | ||
| ROIC | 8.72% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 19.58% | ||
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% | ||
| FCFM | 21.19% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 223.08% | ||
| Cap/Sales | 10.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.33% | ||
| Profit Quality | 130.63% | ||
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 | ||
| Altman-Z | 5.66 |
F-Score7
WACC8.05%
ROIC/WACC1.08
Cap/Depr(3y)950.14%
Cap/Depr(5y)614.59%
Cap/Sales(3y)35.03%
Cap/Sales(5y)23.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y204.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y186.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.62%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 54.3 and the Price/Book (PB) ratio is 12.88.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.